<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CHLORPROMAZINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CHLORPROMAZINE" rxcui="2403">
<ATC code="N05AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="INSULIN" rxcui="">
<ATC code="5856" />
</DRUG>
</DRUG2>
<DESCRIPTION>With strong doses (100 mg per day of chlorpromazine): elevation of glycemia (decrease of the freeing of insulin)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Inform the patient and reinforce self monitoring of blood glucose. Possible adjustment of the dosage of the insulin durin the treatment with the neuroleptic and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CHLORPROMAZINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CHLORPROMAZINE" rxcui="">
<ATC code="2403" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="BLOOD GLUCOSE LOWERING SULFONAMIDES" code="A10BB" /></DRUG2>
<DESCRIPTION>With strong doses (100 mg per day of chlorpromazine): elevation of glycemia (decrease of the freeing of insulin)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Inform the patient and reinforce self monitoring of blood glucose. Possible adjustment of the dosage of the insulin durin the treatment with the neuroleptic and after it is stopped.</COMMENT>
</INTERACTION>
</INTERACTIONS>
